Tags : Riximyo

Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch

Vartika Singh August 19, 2020

Shots: In Jul 2020, following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care […]readmore

Biosimilars

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Tuba Khan June 10, 2020

Shots: Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada Sandoz has received Health Canada’s Notice of Compliance on Apr […]readmore

Tags : Riximyo

Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Riximyo

Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company